Lysophosphatidic Acid Induces Neointima Formation Through PPARγ Activation

Journal of Experimental Medicine

Volumn 199, Issue 6, 2004, Pages 763-774

  Zhang, Chunxiang ^a   Baker, Daniel L ^a,b,c   Yasuda, Satoshi ^c   Makarova, Natalia ^c   Balazs, Louisa ^c   Johnson, Leonard R ^c   Marathe, Gopal K ^d   McIntyre, Thomas M ^e   Xu, Yong ^e   Prestwich, Glenn D ^e   Byun, Hoe Sup ^f   Bittman, Robert ^f   Tigyi, Gabor ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Genom/Bioinfo Ctr of Excellence   (United States)

^c Department of Physiology ^*  (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e Center for Cell Signaling   (United States)

^f CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Atherogenesis; Lipid mediator; LPA; Neointima; PPAR

Indexed keywords

1 O HEXADECYL 2 AZELEOYLPHOSPHATIDYLCHOLINE; 2 CHLORO 5 NITROBENZANILIDE; ALKYL ETHER; CD36 ANTIGEN; EPIDERMAL GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; LIGAND; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID DERIVATIVE; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PHOSPHATIDYLCHOLINE; PLATELET DERIVED GROWTH FACTOR; POLYPEPTIDE; RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; SCAVENGER RECEPTOR; STEAROYLOXOVALERYLPHOSPHATIDYLCHOLINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CAROTID ARTERY; CELL AGGREGATION; CELL DIFFERENTIATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; IN VITRO STUDY; IN VIVO STUDY; INTIMA; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MODIFICATION; RAT; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; TISSUE REPAIR; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANALYSIS OF VARIANCE; ANILIDES; ANIMALS; ANTIGENS, CD36; ARTERIOSCLEROSIS; CALMODULIN-BINDING PROTEINS; CAROTID ARTERY DISEASES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA PRIMERS; GROWTH SUBSTANCES; LIGANDS; LIPOPROTEINS, LDL; LYSOPHOSPHOLIPIDS; MALE; MUSCLE, SMOOTH; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 12144288490     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20031619     Document Type: Article

References (53)

1. Lusis, A.J. 2000. Atherosclerosis. Nature. 407:233-241.
2. Steinberg, D. 2002. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. 8:1211-1217.
3. Dzau, V.J., R.C. Braun-Dullaeus, and D.G. Sedding. 2002. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8:1249-1256.
4. Ross, R. 1999. Atherosclerosis is an inflammatory disease. Am. Heart J. 138:S419-S420.
5. Libby, P. 2002. Inflammation in atherosclerosis. Nature. 420:868-874.
6. McIntyre, T.M., G.A. Zimmerman, and S.M. Prescott. 1999. Biologically active oxidized phospholipids. J. Biol. Chem. 274:25189-25192.
7. Berliner, J.A., G. Subbanagounder, N. Leitinger, A.D. Watson, and D. Vora. 2001. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc. Med. 11:142-147.
8. Siess, W., K.J. Zangl, M. Essler, M. Bauer, R. Brandl, C. Corrinth, R. Bittman, G. Tigyi, and M. Aepfelbacher. 1999. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 96:6931-6936.
9. Tigyi, G., and A. Parrill. 2003. Molecular mechanisms of lysophosphatidic acid action. Prog. Lipid Res. 42:498-526.
10. Spector, A.A. 2003. Plaque rupture, lysophosphatidic acid, and thrombosis. Circulation. 108:641-643.
11. McIntyre, T.M., A.V. Pontsler, A.R. Silva, A. St Hilaire, Y. Xu, J.C. Hinshaw, G.A. Zimmerman, K. Hama, J. Aoki, H. Arai, and G.D. Prestwich. 2003. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc. Natl. Acad. Sci. USA. 100:131-136.
12. Rother, E., R. Brandl, D.L. Baker, P. Goyal, H. Gebhard, G. Tigyi, and W. Siess. 2003. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation. 108:741-747.
13. Berliner, J.A., and J.W. Heinecke. 1996. The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20:707-727.
14. Weidtmann, A., R. Scheithe, N. Hrboticky, A. Pietsch, R. Lorenz, and W. Siess. 1995. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 15:1131-1138.
15. Subbanagounder, G., N. Leitinger, D.C. Schwenke, J.W. Wong, H. Lee, C. Rizza, A.D. Watson, K.F. Faull, A.M. Fogelman, and J.A. Berliner. 2000. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler. Thromb. Vasc. Biol. 20:2248-2254.
16. Davies, S.S., A.V. Pontsler, G.K. Marathe, K.A. Harrison, R.C. Murphy, J.C. Hinshaw, G.D. Prestwich, A.S. Hilaire, S.M. Prescott, G.A. Zimmerman, and T.M. McIntyre. 2001. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J. Biol. Chem. 276:16015-16023.
17. Yoshida, K., W. Nishida, K. Hayashi, Y. Ohkawa, A. Ogawa, J. Aoki, H. Arai, and K. Sobue. 2003. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation. 108:1746-1752.
18. Hayashi, K., M. Takahashi, W. Nishida, K. Yoshida, Y. Ohkawa, A. Kitabatake, J. Aoki, H. Arai, and K. Sobue. 2001. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ. Res. 89:251-258.
19. Xu, Y., L. Qian, and G.D. Prestwich. 2003. Synthesis of alpha-fluorinated phosphonates from α-fluorovinylphosphonates: a new route to analogues of lysophosphatidic acid. Org. Lett. 5:2267-2270.
20. Xu, Y., L. Qian, and G.D. Prestwich. 2003. Synthesis of monofluorinated analogues of lysophosphatidic acid. J. Org. Chem. 68:5320-5330.
21. Yokoyama, K., D.L. Baker, T. Virag, K. Liliom, H.S. Byun, G. Tigyi, and R. Bittman. 2002. Stereochemical properties of lysophosphatidic acid receptor activation and metabolism. Biochim. Biophys. Acta. 1582:295-308.
22. Xu, Y., and G.D. Prestwich. 2002. Synthesis of chiral (α,α-difluoroalkyl)phosphonate analogues of (lyso)phosphatidic acid via hydrolytic kinetic resolution. Org. Lett. 4:4021-4024.
23. Sprecher, D.L., E.J. Schaefer, K.M. Kent, R.E. Gregg, L.A. Zech, J.M. Hoeg, B. McManus, W.C. Roberts, and H.B.J. Brewer. 1984. Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am. J. Cardiol. 54:20-30.
24. Baker, D.L., D.M. Desiderio, D.D. Miller, B. Tolley, and G.J. Tigyi. 2001. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal. Biochem. 292:287-295.
25. Wang, D.A., H. Du, J.H. Jaggar, D.N. Brindley, G.J. Tigyi, and M.A. Watsky. 2002. Injury-elicited differential transcriptional regulation of phospholipid growth factor receptors in the cornea. Am. J. Physiol. Cell Physiol. 283:C1646-C1654.
26. Simon, M.F., H. Chap, and L. Douste-Blazy. 1982. Human platelet aggregation induced by 1-alkyl-lysophosphatidic acid and its analogs: a new group of phospholipid mediators? Biochem. Biophys. Res. Commun. 108:1743-1750.
27. Tokumura, A., K. Fukuzawa, J. Isobe, and H. Tsukatani. 1981. Lysophosphatidic acid-induced aggregation of human and feline platelets: structure-activity relationship. Biochem. Biophys. Res. Commun. 99:391-398.
28. Tokumura, A., M. Iimori, Y. Nishioka, M. Kitahara, M. Sakashita, and S. Tanaka. 1994. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am. J. Physiol. 267:C204-C210.
29. Sugiura, T., S. Nakane, S. Kishimoto, K. Waku, Y. Yoshioka, A. Tokumura, and D.J. Hanahan. 1999. Occurrence of lysophosphatidic acid and its alkyl ether-linked analog in rat brain and comparison of their biological activities toward cultured neural cells. Biochim. Biophys. Acta. 1440:194-204.
30. Tokumura, A., J. Sinomiya, S. Kishimoto, T. Tanaka, K. Kogure, T. Sugiura, K. Satouchi, K. Waku, and K. Fukuzawa. 2002. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids. Biochem. J. 365:617-628.
31. Simon, M.F., A. Rey, I. Castan-Laurel, S. Gres, D. Sibrac, P. Valet, and J.S. Saulnier-Blache. 2002. Expression of ectolipid phosphate phosphohydrolases in 3T3F442A preadipocytes and adipocytes. Involvement in the control of lysophosphatidic acid production. J. Biol. Chem. 277:23131-23136.
32. Sano, T., D. Baker, T. Virag, A. Wada, Y. Yatomi, T. Kobayashi, Y. Igarashi, and G. Tigyi. 2002. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J. Biol. Chem. 277:21197-21206.
33. Fukushima, N., I. Ishii, J.J. Contos, J.A. Weiner, and J. Chun. 2001. Lysophospholipid receptors. Annu. Rev. Pharmacol. Toxicol. 41:507-534.
34. Noguchi, K., S. Ishii, and T. Shimizu. 2003. Identification of p2y9/ GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 278:25600-25666.
35. Bandoh, K., J. Aoki, A. Taira, M. Tsujimoto, H. Arai, and K. Inoue. 2000. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 478:159-165.
36. Fischer, D.J., N. Nusser, T. Virag, K. Yokoyama, D. Wang, D.L. Baker, D. Bautista, A.L. Parrill, and G. Tigyi. 2001. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 60:776-784.
37. Diep, Q.N., and E.L. Schiffrin. 2001. Increased expression of peroxisome proliferator-activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats. Hypertension. 38:249-254.
38. Li, A.C., and C.K. Glass. 2002. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 8:1235-1242.
39. Tugwood, J.D., I. Issemann, R.G. Anderson, K.R. Bundell, W.L. McPheat, and S. Green. 1992. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11:433-439.
40. Leesnitzer, L.M., D.J. Parks, R.K. Bledsoe, J.E. Cobb, J.L. Collins, T.G. Consler, R.G. Davis, E.A. Hull-Ryde, J.M. Lenhard, L. Patel, et al. 2002. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 41:6640-6650.
41. Subbanagounder, G., A.D. Watson, and J.A. Berliner. 2000. Bioactive products of phospholipid oxidation: isolation, identification, measurement and activities. Free Radic. Biol. Med. 28:1751-1761.
42. Febbraio, M., D.P. Hajjar, and R.L. Silverstein. 2001. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108:785-791.
43. Hama, K., K. Bandoh, Y. Kakehi, J. Aoki, and H. Arai. 2002. Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett. 523:187-192.
44. Tigyi, G., A. Henschen, and R. Miledi. 1991. A factor that activates oscillatory chloride currents in Xenopus oocytes copurifies with a subfraction of serum albumin. J. Biol. Chem. 266:20602-20609.
45. Tigyi, G., and R. Miledi. 1992. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J. Biol. Chem. 267:21360-21367.
46. Tokumura, A., T. Tsutsumi, and H. Tsukatani. 1992. Trans-bilayer movement and metabolic fate of ether-linked phosphatidic acid (1-O-octadecyl-2-acetyl-sn-glycerol-3-phosphate) in guinea pig peritoneal polymorphonuclear leukocytes. J. Biol. Chem. 267:7275-7283.
47. Wysowski, D.K., G. Armstrong, and L. Governale. 2003. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care. 26:1852-1855.
48. Rocchi, S., and J. Auwerx. 1999. Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator. Ann. Med. 31:342-351.
49. Chawla, A., Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R.M. Evans. 2001. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7:48-52.
50. Pagano, R.E., and K.J. Longmuir. 1985. Phosphorylation, transbilayer movement, and facilitated intracellular transport of diacylglycerol are involved in the uptake of a fluorescent analog of phosphatidic acid by cultured fibroblasts. J. Biol. Chem. 260:1909-1916.
51. Tokumura, A., T. Tsutsumi, J. Yoshida, and H. Tsukatani. 1990. Translocation of exogenous platelet-activating factor and its lyso-compound through plasma membranes is a rate-limiting step for their metabolic conversions into alkylacylglycerophosphocholines in rabbit platelets and guinea-pig leukocytes. Biochim Biophys Acta. 1044:91-100.
52. Boujaoude, L.C., C. Bradshaw-Wilder, C. Mao, J. Cohn, B. Ogretmen, Y.A. Hannun, and L.M. Obeid. 2001. Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J. Biol. Chem. 276:35258-35264.
53. Homma, H., A. Tokumura, and D.J. Hanahan. 1987. Binding and internalization of platelet-activating factor 1-O-alkyl2-acetyl-sn-glycero-3-phosphocholine in washed rabbit platelets. J. Biol. Chem. 262:10582-10587.